Citation: Lvqin Fu, Xianbin Ma, Yuantong Liu, Zhigang Xu, Zhijun Sun. Applying nanotechnology to boost cancer immunotherapy by promoting immunogenic cell death[J]. Chinese Chemical Letters, ;2022, 33(4): 1718-1728. doi: 10.1016/j.cclet.2021.10.074 shu

Applying nanotechnology to boost cancer immunotherapy by promoting immunogenic cell death

Lvqin Fu ^{a, 1} ,
Xianbin Ma ^{b, 1} ,
Yuantong Liu ^{a, 1} ,
Zhigang Xu ^{b, *,} ,
Zhijun Sun ^{a, *,}

a.
The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan 430079, China
b.
Key Laboratory of Luminescence Analysis and Molecular Sensing, Ministry of Education, School of Materials and Energy & Chongqing Engineering Research Center for Micro-Nano Biomedical Materials and Devices, Southwest University, Chongqing 400715, China

zgxu@swu.edu.cn

sunzj@whu.edu.cn

Received Date: 1 August 2021
Revised Date: 25 October 2021
Accepted Date: 26 October 2021
Available Online: 29 October 2021

Figures(8)

Tumor immunotherapy, especially immune checkpoint blockade (ICB), has revolutionized the cancer field. However, the limited response of tumors to immunotherapy is a major obstacle. Tumor immunogenic cell death (ICD) is a death mode of tumor cells that can promote tumor immunity. ICD can induce strong antitumor immune responses through the ectopic exposure of calreticulin on the plasma membrane surface and the release of the non-histone nuclear protein high-mobility group box 1 (HMGB1), ATP, and interferon (IFN), thus activating an adaptive immune response against dead cell-associated antigens and enhancing the therapeutic effect of tumor immunotherapy. Chemotherapy, radiotherapy, photothermal therapy, magneto-thermodynamics therapy, nanopulse stimulation, and oncolytic virus therapy can all induce a strong antitumor immune response by ICD. In addition, the application of nanotechnology can precisely target drug delivery and improve the efficacy of immunotherapy. Here we introduce the basic concepts and molecular mechanisms underlying the induction of ICD. Then, we summarize and discuss the progress in the application of nanotechnology in immunotherapy to promote ICD. Finally, we attempt to define the challenges and future directions in this area to extend the benefits of ICD to a broader patient population.
- Immunogenic cell death,
- Nanotechnology,
- Cancer immunotherapy,
- Combination therapy,
- Immune checkpoint blockade
1. [1]
  K.J. Hiam-Galvez, B.M. Allen, M.H. Spitzer, Nat. Rev. Cancer21 (2021) 345–359. doi: 10.1038/s41568-021-00347-z
2. [2]
  J.J. Havel, D. Chowell, T.A. Chan, Nat. Rev. Cancer19 (2019) 133–150. doi: 10.1038/s41568-019-0116-x
3. [3]
  P. Hegde, D. Chen, Immunity52 (2020) 17–35. doi: 10.1016/j.immuni.2019.12.011
4. [4]
  P. Sharma, S. Hu-Lieskovan, J.A. Wargo, A. Ribas, Cell168 (2017) 707–723. doi: 10.1016/j.cell.2017.01.017
5. [5]
  Y. Liu, Z. Sun, Theranostics11 (2021) 5365–5386. doi: 10.7150/thno.58390
6. [6]
  S. Li, J. Chen, Z. Sun, Cancer Commun. 41 (2021) 830–850. doi: 10.1002/cac2.12183
7. [7]
  Y. Liu, X. Cao, J. Mol. Med. 94 (2016) 509–522. doi: 10.1007/s00109-015-1376-x
8. [8]
  J. Galon, D. Bruni, Nat. Rev. Drug Discov. 18 (2019) 197–218. doi: 10.1038/s41573-018-0007-y
9. [9]
  J. Huang, B. Yang, Y. Peng, et al., Adv. Funct. Mater. 31 (2021) 2011171. doi: 10.1002/adfm.202011171
10. [10]
  D.S. Chen, I. Mellman, Nature541 (2017) 321–330. doi: 10.1038/nature21349
11. [11]
  P. Bonaventura, T. Shekarian, V. Alcazer, et al., Front. Immunol. 10 (2019) 168. doi: 10.3389/fimmu.2019.00168
12. [12]
  J.A. Trujillo, R.F. Sweis, R. Bao, J.J. Luke, Cancer Immunol. Res. 6 (2018) 990–1000. doi: 10.1158/2326-6066.cir-18-0277
13. [13]
  P.S. Hegde, V. Karanikas, S. Evers, Clin. Cancer Res. 22 (2016) 1865. doi: 10.1158/1078-0432.CCR-15-1507
14. [14]
  Q. Duan, H. Zhang, J. Zheng, L. Zhang, Trends Cancer6 (2020) 605–618. doi: 10.1016/j.trecan.2020.02.022
15. [15]
  L.L. van der Woude, M.A.J. Gorris, A. Halilovic, C.G. Figdor, I.J.M. de Vries, Trends Cancer3 (2017) 797–808. doi: 10.1016/j.trecan.2017.09.006
16. [16]
  A.J. Anandappa, C.J. Wu, P.A. Ott, Cancer Discov. 10 (2020) 185–197. doi: 10.1158/2159-8290.cd-19-0790
17. [17]
  K. Lu, C. He, N. Guo, et al., J. Am. Chem. Soc. 138 (2016) 12502–12510. doi: 10.1021/jacs.6b06663
18. [18]
  Y. Ma, Y. Zhang, X. Li, et al., ACS Nano13 (2019) 11967–11980. doi: 10.1021/acsnano.9b06040
19. [19]
  R. Banerjee, P. Tyagi, S. Li, L. Huang, Int. J. Cancer112 (2004) 693–700. doi: 10.1002/ijc.20452
20. [20]
  M.C. Cochran, J. Eisenbrey, R.O. Ouma, M. Soulen, M.A. Wheatley, Int. J. Pharm. 414 (2011) 161–170. doi: 10.1016/j.ijpharm.2011.05.030
21. [21]
  D.O. Croci, M.F. Zacarías Fluck, M.J. Rico, et al., Cancer Immunol. Immunother. 56 (2007) 1687–1700. doi: 10.1007/s00262-007-0343-y
22. [22]
  Z. Deng, F. Yan, Q. Jin, et al., J. Control. Release174 (2014) 109–116. doi: 10.1016/j.jconrel.2013.11.018
23. [23]
  A.D. Garg, S. More, N. Rufo, et al., Oncoimmunology6 (2017) e1386829. doi: 10.1080/2162402X.2017.1386829
24. [24]
  G. Kroemer, L. Galluzzi, O. Kepp, L. Zitvogel, Annu. Rev. Immunol. 31 (2013) 51–72. doi: 10.1146/annurev-immunol-032712-100008
25. [25]
  O. Kepp, L. Senovilla, I. Vitale, et al., Oncoimmunology3 (2014) e955691. doi: 10.4161/21624011.2014.955691
26. [26]
  A.D. Garg, P. Agostinis, Immunol. Rev. 280 (2017) 126–148. doi: 10.1111/imr.12574
27. [27]
  L. Galluzzi, A. Buqué, O. Kepp, L. Zitvogel, G. Kroemer, Nat. Rev. Immunol. 17 (2017) 97–111. doi: 10.1038/nri.2016.107
28. [28]
  T.S. van Kempen, M.H. Wenink, E.F.A. Leijten, T.R.D.J. Radstake, M. Boes, Nat. Rev. Rheumatol. 11 (2015) 483–492. doi: 10.1038/nrrheum.2015.60
29. [29]
  L. Galluzzi, M.C. Maiuri, I. Vitale, et al., Cell Death Differ. 14 (2007) 1237–1243. doi: 10.1038/sj.cdd.4402148
30. [30]
  D.V. Krysko, A.D. Garg, A. Kaczmarek, et al., Nat. Rev. Cancer12 (2012) 860–875. doi: 10.1038/nrc3380
31. [31]
  L. Galluzzi, A. Buque, O. Kepp, L. Zitvogel, G. Kroemer, Nat. Rev. Immunol. 17 (2017) 97–111. doi: 10.1038/nri.2016.107
32. [32]
  O. Kepp, L. Menger, E. Vacchelli, et al., Cytokine Growth Factor Rev. 24 (2013) 311–318. doi: 10.1016/j.cytogfr.2013.05.001
33. [33]
  E.H. Hall, K.H. Schoenbach, S.J. Beebe, Apoptosis12 (2007) 1721–1731. doi: 10.1007/s10495-007-0083-7
34. [34]
  D. Hanahan, R.A. Weinberg, Cell144 (2011) 646–674. doi: 10.1016/j.cell.2011.02.013
35. [35]
  J. Zhang, L. Shen, X. Li, et al., ACS Nano13 (2019) 12511–12524. doi: 10.1021/acsnano.9b02875
36. [36]
  J. Pol, E. Vacchelli, F. Aranda, et al., Oncoimmunology4 (2015) e1008866. doi: 10.1080/2162402X.2015.1008866
37. [37]
  S. Bai, L. Yang, Y. Wang, et al., Small16 (2020) e2000214. doi: 10.1002/smll.202000214
38. [38]
  V.D. Turubanova, I.V. Balalaeva, T.A. Mishchenko, et al., J. Immunother. Cancer7 (2019) 350. doi: 10.1186/s40425-019-0826-3
39. [39]
  A. Roy, M.S. Singh, P. Upadhyay, S. Bhaskar, Mol. Pharm. 7 (2010) 1778–1788. doi: 10.1021/mp100153r
40. [40]
  J. Kim, L.F. Sestito, S. Im, W.J. Kim, S.N. Thomas, Adv. Funct. Mater. 30 (2020) 1908788. doi: 10.1002/adfm.201908788
41. [41]
  B. Feng, F. Zhou, B. Hou, et al., Adv. Mater. 30 (2018) 1803001. doi: 10.1002/adma.201803001
42. [42]
  J. Lu, X. Liu, Y.P. Liao, et al., ACS Nano12 (2018) 11041–11061. doi: 10.1021/acsnano.8b05189
43. [43]
  K. Sek, C. Mølck, G. Stewart, et al., Int. J. Mol. Sci. 19 (2018) 3837. doi: 10.3390/ijms19123837
44. [44]
  B. Allard, D. Allard, L. Buisseret, J. Stagg, Nat. Rev. Clin. Oncol. 17 (2020) 611–629. doi: 10.1038/s41571-020-0382-2
45. [45]
  J. Qi, F. Jin, Y. You, et al., Nat. Commun. 12 (2021) 4755. doi: 10.1038/s41467-021-24902-2
46. [46]
  Y. Liu, P. Maccarini, G.M. Palmer, et al., Sci. Rep. 7 (2017) 8606. doi: 10.1038/s41598-017-09116-1
47. [47]
  G. Song, L. Cheng, Y. Chao, K. Yang, Z. Liu, Adv. Mater. 29 (2017) 1700996.1700991-1700996.1700926. doi: 10.1002/adma.201700996
48. [48]
  J.P. Fruehauf, F.L. Meyskens, Clin. Cancer Res. 13 (2007) 789–794. doi: 10.1158/1078-0432.CCR-06-2082
49. [49]
  B. Yang, Y. Chen, J. Shi, Chem. Rev. 119 (2019) 4881–4985. doi: 10.1021/acs.chemrev.8b00626
50. [50]
  Z. Huang, Y. Wang, D. Yao, J. Wu, A. Yuan, Nat. Commun. 12 (2021) 145. doi: 10.1038/s41467-020-20243-8
51. [51]
  Q. Chen, J. Chen, Z. Yang, et al., Adv. Mater. 31 (2019) 1802228. doi: 10.1002/adma.201802228
52. [52]
  Y. Chao, L. Xu, C. Liang, et al., Nat. Biomed. Eng. 2 (2018) 611–621. doi: 10.1038/s41551-018-0262-6
53. [53]
  F. Hadi, S. Tavakkol, S. Laurent, et al., J. Cell. Physiol. 234 (2019) 20028–20035. doi: 10.1002/jcp.28599
54. [54]
  Z. Guo, S. Zhu, Y. Yong, et al., Adv. Mater. 29 (2017) 1704136. doi: 10.1002/adma.201704136
55. [55]
  H. Abrahamse, M.R. Hamblin, Biochem. J. 473 (2016) 347–364. doi: 10.1042/BJ20150942
56. [56]
  B. Culhaoglu, A. Akdemir, Curr. Top. Med. Chem. 17 (2017) 1580–1587. doi: 10.2174/1568026616666161222100702
57. [57]
  K. Seidi, H.A. Neubauer, R. Moriggl, R. Jahanban-Esfahlan, T. Javaheri, J. Control. Release275 (2018) 142–161. doi: 10.1016/j.jconrel.2018.02.020
58. [58]
  R. Liang, L. Liu, H. He, et al., Biomaterials177 (2018) 149–160. doi: 10.1016/j.biomaterials.2018.05.051
59. [59]
  L. Shen, T. Zhou, Y. Fan, X. Chang, H. Jiang, Chin. Chem. Lett. 31 (2020) 1709–1716. doi: 10.1016/j.cclet.2020.02.007
60. [60]
  S. Wang, W. Wu, P. Manghnani, et al., ACS Nano13 (2019) 3095–3105. doi: 10.1021/acsnano.8b08398
61. [61]
  F. Bolze, S. Jenni, A. Sour, V. Heitz, Chem. Commun. 53 (2017) 12857–12877. doi: 10.1039/C7CC06133A
62. [62]
  L.L. Yang, L. Zhang, S.C. Wan, et al., Adv. Funct. Mater. (2021), 10.1002/adfm. 202103056.
63. [63]
  H. Tang, H. Li, Z. Sun, Cancer Biol. Med. (2021), 10.20892/j. issn. 2095-3941.2020.0806.
64. [64]
  T. Zhang, H. Xiong, X. Ma, et al., Small Methods5 (2021) 2100115. doi: 10.1002/smtd.202100115
65. [65]
  X. Li, J.F. Lovell, J. Yoon, X. Chen, Nat. Rev. Clin. Oncol. 17 (2020) 657–674. doi: 10.1038/s41571-020-0410-2
66. [66]
  G. Lan, K. Ni, Z. Xu, et al., J. Am. Chem. Soc. 140 (2018) 5670–5673. doi: 10.1021/jacs.8b01072
67. [67]
  L. Liu, H. He, Z. Luo, et al., Adv. Funct. Mater. 30 (2020) 1910176. doi: 10.1002/adfm.201910176
68. [68]
  H. Deng, Z. Zhou, W. Yang, et al., Nano Lett. 20 (2020) 1928–1933. doi: 10.1021/acs.nanolett.9b05210
69. [69]
  X. Mai, Y. Zhang, H. Fan, et al., Biomaterials232 (2020) 119699. doi: 10.1016/j.biomaterials.2019.119699
70. [70]
  G. Deng, Z. Sun, S. Li, et al., ACS Nano12 (2018) 12096–12108. doi: 10.1021/acsnano.8b05292
71. [71]
  W.L. Liu, M.Z. Zou, T. Liu, et al., Adv. Mater. 31 (2019) 1900499. doi: 10.1002/adma.201900499
72. [72]
  C. Zhang, F. Gao, W. Wu, et al., ACS Nano13 (2019) 11249–11262. doi: 10.1021/acsnano.9b04315
73. [73]
  J. Estelrich, M.A. Busquets, Molecules23 (2018) 1567. doi: 10.3390/molecules23071567
74. [74]
  Y. Liu, B.M. Crawford, T. Vo-Dinh, Immunotherapy10 (2018) 1175–1188. doi: 10.2217/imt-2018-0029
75. [75]
  W. Chen, M. Qin, X. Chen, et al., Theranostics8 (2018) 2229–2241. doi: 10.7150/thno.24073
76. [76]
  Y. Liu, P. Bhattarai, Z. Dai, X. Chen, Chem. Soc. Rev. 48 (2019) 2053–2108. doi: 10.1039/C8CS00618K
77. [77]
  G. Bai, P. Yuan, B. Cai, et al., Adv. Funct. Mater. 29 (2019) 1904401. doi: 10.1002/adfm.201904401
78. [78]
  P. Yuan, G. Dou, T. Liu, et al., Biomaterials275 (2021) 120956. doi: 10.1016/j.biomaterials.2021.120956
79. [79]
  X. Duan, Y. Li, Small9 (2013) 1521–1532. doi: 10.1002/smll.201201390
80. [80]
  G.T. Yu, L. Rao, H. Wu, et al., Adv. Funct. Mater. 28 (2018) 1801389. doi: 10.1002/adfm.201801389
81. [81]
  E.A. Hussein, M.M. Zagho, G.K. Nasrallah, A.A. Elzatahry, Int. J. Nanomed. 13 (2018) 2897–2906. doi: 10.2147/ijn.s161031
82. [82]
  Y. Yu, M. Zhou, W. Zhang, et al., Mol. Pharm. 16 (2019) 1929–1938. doi: 10.1021/acs.molpharmaceut.8b01298
83. [83]
  W. Li, J. Yang, L. Luo, et al., Nat. Commun. 10 (2019) 3349. doi: 10.1038/s41467-019-11269-8
84. [84]
  J. Wang, J. Meng, W. Ran, et al., Nano Lett. 19 (2019) 5266–5276. doi: 10.1021/acs.nanolett.9b01717
85. [85]
  R. Nuccitelli, A. McDaniel, S. Anand, et al., J. Immunother. Cancer5 (2017) 32. doi: 10.1186/s40425-017-0234-5
86. [86]
  S. Guo, N.I. Burcus, J. Hornef, et al., Cancers10 (2018) 217. doi: 10.3390/cancers10070217
87. [87]
  S. Guo, Y. Jing, N.I. Burcus, et al., Int. J. Cancer142 (2018) 629–640. doi: 10.1002/ijc.31071
88. [88]
  X. Liu, B. Yan, Y. Li, et al., ACS Nano14 (2020) 1936–1950. doi: 10.1021/acsnano.9b08320
89. [89]
  X. Liu, J. Zheng, W. Sun, et al., ACS Nano13 (2019) 8811–8825. doi: 10.1021/acsnano.9b01979
90. [90]
  Y. Chao, G. Chen, C. Liang, et al., Nano Lett. 19 (2019) 4287–4296. doi: 10.1021/acs.nanolett.9b00579
91. [91]
  H.L. Kaufman, F.J. Kohlhapp, A. Zloza, Nat. Rev. Drug. Discov. 14 (2015) 642–662. doi: 10.1038/nrd4663
92. [92]
  P.K. Bommareddy, M. Shettigar, H.L. Kaufman, Nat. Rev. Immunol. 18 (2018) 498–513. doi: 10.1038/s41577-018-0014-6
93. [93]
  J.R. Hamilton, G. Vijayakumar, P. Palese, Cell Rep. 22 (2018) 1–7. doi: 10.1016/j.celrep.2017.12.025
94. [94]
  C. Chu, H. Lin, H. Liu, et al., Adv. Mater. 29 (2017) 1605928. doi: 10.1002/adma.201605928
95. [95]
  J. Wu, J. Chen, Y. Feng, et al., Sci. Adv. 6 (2020) eabc7828. doi: 10.1126/sciadv.abc7828
96. [96]
  M. Li, S. Li, H. Zhou, et al., Nat. Commun. 11 (2020) 1126. doi: 10.1038/s41467-020-14963-0
97. [97]
  Y. Dong, Y. Tu, K. Wang, et al., Angew. Chem. Int. Ed. 59 (2020) 7168–7172. doi: 10.1002/anie.201913522
98. [98]
  F. Zhou, B. Feng, H. Yu, et al., Adv. Mater. 31 (2019) 1805888. doi: 10.1002/adma.201805888
99. [99]
  Y. Yang, J. Tang, P.L. Abbaraju, et al., Angew. Chem. Int. Ed. 57 (2018) 11764–11769. doi: 10.1002/anie.201807595
100. [100]
  R. Kuai, L.J. Ochyl, K.S. Bahjat, A. Schwendeman, J.J. Moon, Nat. Mater. 16 (2017) 489–496. doi: 10.1038/nmat4822
101. [101]
  P. Yuan, T. Yang, T. Liu, et al., Biomaterials262 (2020) 120357. doi: 10.1016/j.biomaterials.2020.120357
102. [102]
  F.Y. Huang, J. Lei, Y. Sun, et al., Oncoimmunology7 (2018) e1446720. doi: 10.1080/2162402X.2018.1446720
103. [103]
  L. Feng, L. Cheng, Z. Dong, et al., ACS Nano11 (2017) 927–937. doi: 10.1021/acsnano.6b07525
104. [104]
  M. Hu, J. Zhang, L. Kong, Y. Yu, Z. Zhang, ACS Nano15 (2021) 3123–3138. doi: 10.1021/acsnano.0c09681
105. [105]
  K.M. Au, R. Balhorn, M.C. Balhorn, S.I. Park, A.Z. Wang, ACS Cent. Sci. 5 (2019) 122–144. doi: 10.1021/acscentsci.8b00746
106. [106]
  H. Wang, K. Wang, L. He, et al., Biomaterials244 (2020) 119964. doi: 10.1016/j.biomaterials.2020.119964
107. [107]
  J. Huang, B. Yang, Y. Peng, et al., Adv. Funct. Mater. 31 (2021) 2011171. doi: 10.1002/adfm.202011171
108. [108]
  J. Fucikova, O. Kepp, L. Kasikova, et al., Cell Death Dis. 11 (2020) 1013. doi: 10.1038/s41419-020-03221-2
109. [109]
  K. Twumasi-Boateng, J.L. Pettigrew, Y. Kwok, J.C. Bell, B.H. Nelson, Nat. Rev. Cancer18 (2018) 419–432. doi: 10.1038/s41568-018-0009-4
110. [110]
  J. Zhou, G. Wang, Y. Chen, et al., J. Cell Mol. Med. 23 (2019) 4854–4865. doi: 10.1111/jcmm.14356
111. [111]
  R. Song, T. Li, J. Ye, et al., Adv. Mater. (2021), 10.1002/adma. 202101155 (2021) e2101155. doi: 10.1002/adma.202101155
112. [112]
  L. Sun, F. Shen, L. Tian, et al., Adv. Mater. 33 (2021) e2007910. doi: 10.1002/adma.202007910
113. [113]
  H. Li, Z. Wang, Z. Chen, et al., Nat. Commun. 12 (2021) 2773. doi: 10.1038/s41467-021-22674-3
114. [114]
  J.D. Martin, H. Cabral, T. Stylianopoulos, R.K. Jain, Nat. Rev. Clin. Oncol. 17 (2020) 251–266. doi: 10.1038/s41571-019-0308-z
115. [115]
  Y. Shi, T. Lammers, Acc. Chem. Res. 52 (2019) 1543–1554. doi: 10.1021/acs.accounts.9b00148
116. [116]
  L. Guo, D.D. Yan, D. Yang, et al., ACS Nano8 (2014) 5670–5681. doi: 10.1021/nn5002112
117. [117]
  L. Yang, S. Zhu, Z. He, et al., Chin. Chem. Lett. 33 (2022) 314–319. doi: 10.1016/j.cclet.2021.07.007
118. [118]
  B. Chen, L. Mei, R. Fan, et al., Chin. Chem. Lett. 32 (2021) 1775–1779. doi: 10.1016/j.cclet.2020.12.058
119. [119]
  A.D. Garg, L. Galluzzi, L. Apetoh, et al., Front. Immunol. 6 (2015) 588.
1. [1]
  Liangliang Jia , Ye Hong , Xinyu He , Ying Zhou , Liujiao Ren , Hongjun Du , Bin Zhao , Bin Qin , Zhe Yang , Di Gao . Fighting hypoxia to improve photodynamic therapy-driven immunotherapy: Alleviating, exploiting and disregarding. Chinese Chemical Letters, 2025, 36(2): 109957-. doi: 10.1016/j.cclet.2024.109957
2. [2]
  Kun-Heng Li , Hong-Yang Zhao , Dan-Dan Wang , Ming-Hui Qi , Zi-Jian Xu , Jia-Mi Li , Zhi-Li Zhang , Shi-Wen Huang . Mitochondria-targeted nano-AIEgens as a powerful inducer for evoking immunogenic cell death. Chinese Chemical Letters, 2024, 35(5): 108882-. doi: 10.1016/j.cclet.2023.108882
3. [3]
  An Lu , Yuhao Guo , Yi Yan , Lin Zhai , Xiangyu Wang , Weiran Cao , Zijie Li , Zhixia Zhao , Yujie Shi , Yuanjun Zhu , Xiaoyan Liu , Huining He , Zhiyu Wang , Jian-Cheng Wang . Nanomedicine integrating the lipidic derivative of 5-fluorouracil, miriplatin and PD-L1 siRNA for enhancing tumor therapy. Chinese Chemical Letters, 2024, 35(6): 108928-. doi: 10.1016/j.cclet.2023.108928
4. [4]
  Ningyue Xu , Jun Wang , Lei Liu , Changyang Gong . Injectable hydrogel-based drug delivery systems for enhancing the efficacy of radiation therapy: A review of recent advances. Chinese Chemical Letters, 2024, 35(8): 109225-. doi: 10.1016/j.cclet.2023.109225
5. [5]
  Tingting Hu , Chao Shen , Xueyan Wang , Fengbo Wu , Zhiyao He . Tumor microenvironment-sensitive polymeric nanoparticles for synergetic chemo-photo therapy. Chinese Chemical Letters, 2024, 35(11): 109562-. doi: 10.1016/j.cclet.2024.109562
6. [6]
  Wen Xiao , Fazhan Wang , Yangzhuo Gu , Xi He , Na Fan , Qian Zheng , Shugang Qin , Zhongshan He , Yuquan Wei , Xiangrong Song . PEG400-mediated nanocarriers improve the delivery and therapeutic efficiency of mRNA tumor vaccines. Chinese Chemical Letters, 2024, 35(5): 108755-. doi: 10.1016/j.cclet.2023.108755
7. [7]
  Yujie Li , Ya-Nan Wang , Yin-Gen Luo , Hongcai Yang , Jinrui Ren , Xiao Li . Advances in synthetic biology-based drug delivery systems for disease treatment. Chinese Chemical Letters, 2024, 35(11): 109576-. doi: 10.1016/j.cclet.2024.109576
8. [8]
  Xinyue Lan , Junguang Liang , Churan Wen , Xiaolong Quan , Huimin Lin , Qinqin Xu , Peixian Chen , Guangyu Yao , Dan Zhou , Meng Yu . Photo-manipulated polyunsaturated fatty acid-doped liposomal hydrogel for flexible photoimmunotherapy. Chinese Chemical Letters, 2024, 35(4): 108616-. doi: 10.1016/j.cclet.2023.108616
9. [9]
  Shuheng Zhang , Yuanyuan Zhang , Wanyu Wang , Yuzhu Hu , Xinchuan Chen , Bilan Wang , Xiang Gao . A combination strategy of DOX and VEGFR-2 targeted inhibitor based on nanomicelle for enhancing lymphoma therapy. Chinese Chemical Letters, 2024, 35(12): 109658-. doi: 10.1016/j.cclet.2024.109658
10. [10]
  Huijie An , Chen Yang , Zhihui Jiang , Junjie Yuan , Zhongming Qiu , Longhao Chen , Xin Chen , Mutu Huang , Linlang Huang , Hongju Lin , Biao Cheng , Hongjiang Liu , Zhiqiang Yu . Luminescence-activated Pt(Ⅳ) prodrug for in situ triggerable cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109134-. doi: 10.1016/j.cclet.2023.109134
11. [11]
  Mengjuan Sun , Muye Zhou , Yifang Xiao , Hailei Tang , Jinhua Chen , Ruitao Zhang , Chunjiayu Li , Qi Ya , Qian Chen , Jiasheng Tu , Qiyue Wang , Chunmeng Sun . Reversibly size-switchable polyion complex micelles for antiangiogenic cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109110-. doi: 10.1016/j.cclet.2023.109110
12. [12]
  Xiaofang Luo , Ye Wu , Xiaokun Zhang , Min Tang , Feiye Ju , Zuodong Qin , Gregory J Duns , Wei-Dong Zhang , Jiang-Jiang Qin , Xin Luan . Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chinese Chemical Letters, 2025, 36(1): 109724-. doi: 10.1016/j.cclet.2024.109724
13. [13]
  Wenbin Zhou , Yafei Gao , Xinyu Feng , Yanqing Zhang , Cong Yang , Lanxi He , Fenghe Zhang , Xiaoguang Li , Qing Li . Biomimetic nanoplatform integrates FRET-enhanced photodynamic therapy and chemotherapy for cascaded revitalization of the tumor immune microenvironment in OSCC. Chinese Chemical Letters, 2025, 36(1): 109763-. doi: 10.1016/j.cclet.2024.109763
14. [14]
  Jia-Qi Feng , Xiang Tian , Rui-Ge Cao , Yong-Xiu Li , Wen-Long Liu , Rong Huang , Si-Yong Qin , Ai-Qing Zhang , Yin-Jia Cheng . An AIE-based theranostic nanoplatform for enhanced colorectal cancer therapy: Real-time tumor-tracking and chemical-enhanced photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109657-. doi: 10.1016/j.cclet.2024.109657
15. [15]
  Huijiao Fu , Peiqin Liang , Qianwen Chen , Yan Wang , Guang Li , Xuzi Cai , Shengtao Wang , Kun Chen , Shengying Shi , Zhiqiang Yu , Xuefeng Wang . COX-2 blocking therapy in cisplatin chemosensitization of ovarian cancer: An allicin-based nanomedicine approach. Chinese Chemical Letters, 2024, 35(8): 109241-. doi: 10.1016/j.cclet.2023.109241
16. [16]
  Qiang Li , Jiangbo Fan , Hongkai Mu , Lin Chen , Yongzhen Yang , Shiping Yu . Nucleus-targeting orange-emissive carbon dots delivery adriamycin for enhanced anti-liver cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108947-. doi: 10.1016/j.cclet.2023.108947
17. [17]
  Yihan Zhou , Duo Gao , Yaying Wang , Li Liang , Qingyu Zhang , Wenwen Han , Jie Wang , Chunliu Zhu , Xinxin Zhang , Yong Gan . Worm-like micelles facilitate the intestinal mucus diffusion and drug accumulation for enhancing colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(6): 108967-. doi: 10.1016/j.cclet.2023.108967
18. [18]
  Ling-Ling Wu , Xiangchuan Meng , Qingyang Zhang , Xiaowan Han , Feiya Yang , Qinghua Wang , Hai-Yu Hu , Nianzeng Xing . Heavy-atom engineered hypoxia-responsive probes for precisive photoacoustic imaging and cancer therapy. Chinese Chemical Letters, 2024, 35(4): 108663-. doi: 10.1016/j.cclet.2023.108663
19. [19]
  Lin Li , Bingjun Sun , Jin Sun , Lin Chen , Zhonggui He . Binary prodrug nanoassemblies combining chemotherapy and ferroptosis activation for efficient triple-negative breast cancer therapy. Chinese Chemical Letters, 2024, 35(10): 109538-. doi: 10.1016/j.cclet.2024.109538
20. [20]
  Yang Liu , Yan Liu , Kaiyin Yang , Zhiruo Zhang , Wenbo Zhang , Bingyou Yang , Hua Li , Lixia Chen . A selective HK2 degrader suppresses SW480 cancer cell growth by degrading HK2. Chinese Chemical Letters, 2024, 35(8): 109264-. doi: 10.1016/j.cclet.2023.109264

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(809)
HTML views(197)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142